Table 2.
Overall CDI recurrence rates from all studies and large size studies
| Country | All identified studies | Large size studies | ||||
|---|---|---|---|---|---|---|
| No. | Overall recurrence rate (%) | No. | Overall recurrence rate (%) | |||
| Median | Range | Median | Range | |||
| Australia | 0 | N/A | N/A | 0 | N/A | N/A |
| Canada | 4 | 23.66% | 10.40–36.05% | 2 | 18.14% | 10.40–28.84% |
| China | 3 | 10.57% | 3.06–13.33% | 1 | 7.80% | 3.06–8.00% |
| France | 2 | 8.93% | 6.10–11.76% | 1 | 6.10% | N/A |
| Germany | 4 | 17.14% | 6.67–23.00% | 1 | 18.15% | 14.67–18.77% |
| Italy | 4 | 14.60% | 7.70–20.00% | 1 | 15.26% | 14.60–15.92% |
| Japan | 4 | 5.40% | 3.80–18.42% | 2 | 11.61% | 4.80–18.42% |
| Poland | 1 | 21.70% | 5.68–41.18% | 1 | 21.70% | 5.68–41.18% |
| Spain | 5 | 12.71% | 0.00–57.14% | 1 | 57.14% | N/A |
| United Kingdom | 2 | 19.32% | 7.00–21.63% | 1 | 21.63% | N/A |
| United States | 28 | 20.22% | 2.14–64.00% | 16 | 17.45% | 2.14–38.64% |
| Overall | 57 | 17.00% | 0.00–64.00% | 27 | 17.34% | 2.14–57.14% |
Abbreviation: N/A Not applicable, No. Number of key studies reporting outcome